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a  b  s  t  r  a  c  t
Epidemiological  studies  suggested  that  plant-based  dietary  supplements  can  reduce  the
risk of  liver  cancer.  Nexrutine  (NX),  an  herbal  extract  from  Phellodendronamurense, has
been shown  to  have  anti-inﬂammatory,  anti-microbial  and  anti-tumor  activities.  In  the
present  study,  we  have  shown  the  anti-tumor  potential  of  NX against  Solt-Farber  model
with elimination  of PH,  rat  liver  tumor  induced  by  diethylnitrosoamine  (DEN)  as  carcinogen
and  2-acetylaminoﬂuorene  (2-AAF)  as  co-carcinogen.  The  elucidation  of mechanistic  path-
ways  was  explored  in  human  liver  cancer  cells.  Dietary  intake  of NX  signiﬁcantly  decreased
the cell  proliferation  and  inﬂammation,  as  well  as increased  apoptosis  in  the liver  sections
of DEN/2-AAF-treated  rats.  Moreover,  NX  (2.5–10  g/ml)  exposure  signiﬁcantly  decreased
the viability  of liver  cancer  cells  and  modulated  the  levels  of Bax  and  Bcl-2  proteins  levels.
NX treatment  resulted  in increased  cytochrome-c  release  and  cleavage  of  caspases  3  and  9.
In  addition,  NX decreased  the expression  of  CDK2,  CDK4  and  associated  cyclins  E1  and  D1,
while  up-regulated  the expression  of p21,  p27  and  p53  expression.  NX  also  enhanced  phos-
phorylation  of the  mitogen-activated  protein  kinases  (MAPKs)  ERK1/2,  p38  and  JNK1/2.
Collectively,  these  ﬁndings  suggested  that  NX-mediated  protection  against  DEN/2-AAF-
induced  liver  tumorigenesis  involves  decrease  in  cell  proliferation  and  enhancement  in
apoptotic  cell  death  of liver  cancer  cells.
©  2014  Published  by  Elsevier  Ireland  Ltd.  This  is  an open  access  article  under  the  CC
Y-NC-NB
. Introduction
Hepatocellular carcinoma (HCC) is the sixth most
ommon cancer in the world. The incidence of HCC is
ramatically increasing and is the third-leading cause of
ancer death in worldwide (Ferlay et al. [50]). The major
isk factors for hepatic cancer include chronic infection
ith hepatitis B and C (accounting for 54% and 31% of cases
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worldwide respectively), the consumption of food grains
contaminated with mycotoxins (produced by fungi during
storage in tropical or sub-tropical climatic countries) and
last, but not the least, heavy alcohol consumption [1–3].
Hepatocarcinogenesis involves initial genotoxic insult (ini-
tiation), clonal expansion from premalignant to malignant
lesions (promotion) and ﬁnally tumor progression by
means of further clonal expansion [4]. To date, surgery
remains the best choice of treatment that could prolong
HCC patients’ survival. However, poor prognosis at times
after surgery along with side effects of various chemother-
apeutic drugs are also being seen as causes of relapse [5].
e under the CC BY-NC-ND license
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In addition to surgery, chemoprevention is another key
approach to control HCC, where one or more nontoxic, nat-
urally occurring or synthetic agents are administrated to
prevent, improve or reverse the occurrence of disease sub-
stantially. Thus, chemopreventive intervention may  serve
as a feasible alternative strategy for prevention of liver
tumorigenesis.
In recent years, considerable efforts have been made to
search naturally occurring substances for the intervention
of carcinogenesis [6,7]. Nexrutine® (NX), a commer-
cially available herbal extract from Phellodendronamurense,
widely used for the treatment of inﬂammation, gastroen-
teritis, abdominal pain and diarrhea, has shown to exhibit
minimal toxicity to normal tissues [8]. Active components
of NX are isoquinoline alkaloids, phenolic compounds
and ﬂavone glycosides. A recent study revealed that NX
inhibited the proliferation of prostate and lung cancer
cells through the modulation of Akt and CREB-mediated
signaling pathways, and that its anti-proliferative effects
are comparable to that of berberine, a well-known chemo-
preventive agent [9–11]. Other ﬁndings also established NX
to be effective against early-stage prostate tumor devel-
opment as well as tumor progression in the transgenic
adenocarcinoma of mouse prostate (TRAMP) model [8,12].
In addition, recently our group showed that NX inhibited
the promotion of skin tumorigenesis in the two-stage
mouse skin tumorigenesis model [13]. Although NX has
proven to be a potent anti-cancer agent for prostate, skin
and lung cancer, no study so far has reported the anti-tumor
effects of NX on liver cancer.
Therefore, in this study, anti-inﬂammatory and anti-
tumor promoting potential of NX was demonstrated
in partially modiﬁed Solt-Farber rat liver tumorigenesis
model. We  found NX’s anti-tumor mechanisms involved
inhibition of cell proliferation and induction of apopto-
sis, mediated by modulation of p53 and cyclin-dependent
kinase (CDK) inhibitor levels, alternations in mitogen-
activated protein kinases (MAPKs) signaling and activation
of caspases 3 and 9.
2. Materials and methods
2.1. Preparation of NX
Nexrutine® (NX) was obtained from Next Pharmaceut-
icals (Irvine, CA). Stock solution of NX was prepared by
dissolving NX in dimethylsulfoxide (DMSO) at a concen-
tration of 1.0 mg/ml. The stock solution was further diluted
either in milli Q water or culture medium to obtain various
working concentrations.
2.2. Antibodies and chemicals
Antibodies speciﬁc for cyclooxygenase-2 (COX-2) and
inducible nitric oxide synthase (iNOS) were procured
from Cayman Chemical Company (Ann Arbor, MI). Anti-
bodies speciﬁc for ERK1/2, p38, JNK, CDK2, CDK4, p27,
p53, p21, cytochrome c, cyclin E1, cyclin D1 and -
Actin-HRP were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), while p-ERK1/2, p-p38, p-JNK, Bax, Bcl-
2, cleaved-caspase 3, cleaved-caspase 9, and proliferatingports 2 (2015) 1–11
cell nuclear antigen (PCNA) were purchased from cell
signaling (Beverly, MA). 2-Acetylaminoﬂuorene (2-AAF), 2-
 mercaptoethanol (BME), bovine serum albumin (BSA),
dimethyl sulfoxide (DMSO), diethylnitrosamine (DEN),
dithiothreitol (DTT), Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM), Fetal bovine serum (FBS), streptomycin, peni-
cillin, ethylenediaminetetraacetic acid (EDTA) disodium
salt, trypsin/EDTA solution, 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), phenylmethyl-
sulphonyl ﬂuoride (PMSF), propidium iodide (PI), RNase A,
protease inhibitor cocktail set-I, Tris buffer, Triton X-100
and Tween-20 were from Sigma Chemicals Co. (St. Louis,
MO). All other chemicals and reagents used were of highest
purity commercially available.
2.3. Animals
Four to six week old male Wistar rats (160–180 g), were
obtained from the animal breeding colony of CSIR-Indian
Institute of Toxicology Research (CSIR-IITR), Lucknow,
acclimatized under standard laboratory conditions and
given a commercial pellet diet (Provimi Animal Nutrition
India Pvt Limited, India) and water ad libitum. Animals
were housed in plastic cages on rice husk as bedding and
maintained in controlled atmosphere of 12 h dark/light
cycle, 22 ± 2 ◦C temperature and 50–60% humidity as per
rules laid down by Animal Welfare Committee of CSIR-
IITR, Lucknow. All the experiments involving animals were
approved by the Institutional Animal Ethics Committee
(IAEC), CSIR-IITR, Lucknow. Animals were sacriﬁced by cer-
vical dislocation with minimal suffering as per CSIR-IITR
guidelines.
2.4. Animal experimental protocol
To study the protective effect of NX slightly mod-
iﬁed experimental schedule of Solt and Farber liver
tumorigenesis protocol was followed [14,15]. This modi-
ﬁed experimental protocol eliminates partial hepatectomy
(PH). Because, PH is desirable to increase the sensitivity
with weak agents and PH requires extensive surgical pro-
cedure that causes a lot of pain and mortality of animals.
In the classical Solt-Farber model, along with 2-AAF, PH
was  done for vigorous liver cell proliferation and in this
protocol growth can be grossly visible within a period of
1 week. While literature suggest that alone 2-AAF is sufﬁ-
cient to induce tumorigenesis in rats by stimulation of cell
proliferation [16]. Therefore, in the present study, we  have
used a combination of DEN + 2-AAF to develop hepatotu-
morigenesis in Wistar rats. Here, thirty male Wistar rats
were randomly allocated into ﬁve groups of six rat each.
Animals of Group I received only saline intraperitoneally
and kept on normal basal diet. Group II animals were initi-
ated by single intraperitoneal injection of 200 mg/kg body
weight of DEN in saline followed by 2-AAF (0.02% (w/w) in
diet from day 14 until 8 weeks after initiation). Groups III
and IV were served as prevention groups, where in addition
to carcinogen treatment as in Group II, animals received
dietary administration of NX at doses of 300 and 600 ppm
respectively, along with 2-AAF. Group V served as a neg-
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or 8 weeks. Eight weeks after initiation period, animals
n all the groups were observed for any apparent signs of
oxicity as well as mortality, were fasted overnight and sac-
iﬁed. Livers were excised, part of which was used for whole
ell lysate preparation and part ﬁxed in 10% formalin for
istopathologycal and immunohistopathological analysis.
.5. Histopathological evaluation
The formalin-ﬁxed tissue samples were processed
onventionally to prepare parafﬁn blocks followed by tis-
ue sectioning at 5 m and hematoxylin-eosin staining.
tained slides were observed under light microscope of
eica (Heerbrugg, Switzerland) and photographed.
.6. Immunohistochemical analysis
Immunohistochemical analysis of COX-2, iNOS and
CNA were performed in liver sections using Super Sen-
itive Polymer-HRP Detection System from BioGenex (San
amon, CA) as per the manufacturer’s instructions.
.7. In situ cell death detection using TUNEL assay
In situ apoptosis analysis was performed in the parafﬁn-
mbedded liver sections by the TUNEL method using in situ
ell death detection kit (Roche Diagnostics, Indianapolis, IN,
SA) according to manufacturer’s protocol.
.8. Cell culture
The liver cancer cell line (HepG2) cells, were obtained
rom National Centre for Cell Science, Pune, India. Cells
ere cultured in DMEM supplemented with heat inactiv-
ted FBS (10%), penicillin (100 U/ml) and streptomycin
100 U/ml) at 37 ◦C in humid air containing 5% CO2.
.9. Cell growth and viability assay
The liver cancer cells were plated at 5000 cells/cm2 in
8-well plate as described above. At 60–70% conﬂuency,
he cells were fed with fresh medium and treated either
ith DMSO alone or different concentrations (1.0, 2.5, 5.0,
0.0 and 25 g/ml) of NX in DMSO for 24 and 48 h. Via-
ility of the HepG2 cells were determined by MTT  assay
s described previously [17]. The effect of NX on cell via-
ility is presented as the relative cell viability compared
ith vehicle-treated control cells, which were arbitrarily
ssigned 100% viability.
.10. Analysis of apoptotic cell death and cell cycle
istribution by ﬂow cytometer
Liver cancer cells (60–70% conﬂuent) were seeded in 6-
ell cell culture plate at a concentration of 5 × 105 cells/ml
nd treated with NX at concentrations of 2.5, 5.0 and
0.0 g/ml for 48 h, and both adherent and ﬂoating cells
ere collected, washed twice with ice-cold phosphate-
uffered saline and 5.0 × 105 cells were used for apoptosis
nalysis using Annexin V: FITC Apoptosis Detection Kit
BD Pharmingen, San Jose, CA) as per the manufacturer’sports 2 (2015) 1–11 3
instructions using FACS CantoTM II (Becton Dickinson,
Franklin Lakes, NJ) ﬂow cytometer. For cell cycle analysis,
5.0 × 105 cells were ﬁxed in 70% ethanol for 1 h at −20 ◦C
and subsequently incubated with PI (20 g/ml) and RNase
A (200 g/ml) for another 30 min  at 37 ◦C and a minimum of
10,000 events per sample were acquired in ﬂow cytometer
and DNA histograms were analyzed by FACS Diva software
(Becton Dickinson, Franklin Lakes, NJ).
2.11. Protein extraction and western blot analysis
In another set of experiment, liver cancer cells (60–70%
conﬂuent) were treated with either DMSO or NX (0,
2.5, 5.0 and 10.0 g/ml) and after 48 h, cells were har-
vested, washed with cold phosphate-buffered saline,
and lysed with ice-cold RIPA (Radio-immunoprecipitation
Assay) buffer supplemented with protease inhibitors. Pro-
teins (50 g) were subjected to 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to
a polyvinylidene diﬂuoride membrane (Millipore, Billerica,
MA)  and incubated with speciﬁc primary antibodies at 4 ◦C
overnight, followed by incubation with HRP-conjugated
secondary antibody (Sigma, St. Louis, MO). Bound anti-
body was detected by enhanced chemiluminescence using
Luminata Forte Western HRP substrate following the man-
ufacturer’s instructions (Millipore, Billerica, MA). All the
blots were stripped and reprobed for either total of respec-
tive protein or -actin to ensure equal loading of protein.
2.12. Statistical analysis
The results were expressed as the mean ± S.E. The sta-
tistical signiﬁcance of difference between the values of
control and treatment groups was  determined using two-




During the entire period of our study no difference in
food or water consumption was  observed among the var-
ious groups of animals. All the animals had a steady body
weight during the treatment. The administration of DEN/2-
AAF alone or along with NX (300 or 600 ppm) did not affect
the growth of the rats measured at weekly interval.
3.2. Effect of Nexrutine in DEN/2-AAF-induced
histopathological changes
Rats treated with DEN/2-AAF showed abnormal hep-
atocyte shape (Fig. 1B). These cells were small with large
hyperchromatic nuclei compared to liver cells from control
rats (Fig. 1A) and showed cytoplasmic granulation and
intracytoplasmic violet-colored material. Treatment of
animals with 300 pm NX along with DEN/2-AAF showed
slightly enhanced hepatocellular architecture (Fig. 1C),
while the liver architecture of rats those that received
600 ppm NX (Fig. 1D) were comparable to that of the
4 S. Alam et al. / Toxicology Reports 2 (2015) 1–11
Fig. 1. Effect of Nexrutine on histopathology of DEN/2-AAF-treated rat liver. Control group rat liver (A) showed normal cellular architecture while DEN/2-
AAF-treated rat liver (B) showed areas with cytoplasmic granulation, enlarged hyperchromatic nuclei and intracytoplasmic violaceous material. The group
, respec
 (E) shotreated  with DEN/2-AAF along with NX (300 ppm and 600 ppm; C and D
over  the DEN/2-AAF-treated livers. NX (600 ppm)-treated rat liver section
normal rat (Fig. 1A). The size of the nuclei of mononuclear
cells in the liver of NX-treated group was essentially
uniform and fewer binucleated cells were seen in these
rats compared to the DEN/2-AAF treated group (Fig. 1B).
3.3. Inhibitory effect of Nexrutine on DEN/2-AAF-induced
COX-2 and iNOS protein expression
COX-2 and iNOS are well-established molecular
biomarkers of inﬂammation and tumor promotion and thus
could be promising molecular targets for designing of drugs
targeting cancer prevention as well as therapy [18,19]. In
the present study, we observed that both COX-2 and iNOS
protein expression were elevated in DEN/2-AAF-treated rat
liver (Figs 2B and 3B) respectively. Interestingly, dietary
exposure of NX (300 and 600 ppm) resulted in substantial
decrease in COX-2 and iNOS expression in DEN/2-AAF-
treated rat liver (Figs 2C–D and 3C–D) respectively. These
results suggest that NX suppresses DEN/2-AAF-induced
inﬂammation by down regulating COX-2 and iNOS expres-
sion in the rat liver.
3.4. Inhibitory effect of dietary Nexrutine on PCNA
labeling indexPCNA is an auxiliary protein of DNA polymerase-delta
and higher level of its expression is correlated with cell
proliferation, suggesting PCNA is an excellent marker oftively) showed marginal to moderate improvement of hepatic histology
ws near-normal architecture.
cellular proliferation [20]. In our study, the PCNA antigen
was  not expressed in liver sections of control rats (Fig. 4A).
However, liver sections from DEN/2-AAF-treated rats were
positive for the PCNA staining, indicative of active cell pro-
liferation in liver tissue (Fig. 4B). We  observed lower PCNA
expression (Fig. 4C–D) in the treatment groups of NX with
DEN/2-AAF suggesting NX has an anti-proliferative effect
on DEN/2-AAF-induced liver tumorigenesis in rats.
3.5. Nexrutine induced apoptosis in liver tissue treated
with DEN/2-AAF animals
An apoptotic response of NX in the liver tissue of
DEN/2-AAF-induced rats was  investigated using TUNEL
staining. Representative photographs for TUNEL-positive
cells in DEN/2-AAF-treated alone or NX with DEN/2-AAF-
treated animals are shown in Fig. 5. There was an increase
in the number of TUNEL positive cells in the livers of
NX +DEN/2-AAF treated rats (Fig. 5C–D) compared to
DEN/2-AAF-treated rats (Fig. 5B). However, the apoptotic
induction by NX was more pronounced in the group where
600 ppm of NX was given along with DEN/2-AAF (Fig. 5D).
3.6. Nexrutine treatment resulted inhibition in cell
growth of liver cancer cells
The inhibitory effect of NX (0.5–20.0 g/ml) on the
growth of liver cancer cells was assessed by MTT  assay and
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Fig. 2. Effect of Nexrutine on DEN/2-AAF-induced COX-2 expression in rat liver. Livers of DEN/2-AAF-treated rats (B) showed overexpression of COX-2
compared to control livers (A), while that of rats treated with DEN/2-AAF along with 300 ppm (C) and 600 ppm (D) NX showed marginal and signiﬁcant
reduction in COX-2 overexpression, respectively, compared to DEN/2-AAF treatment alone. NX (600 ppm)-treated rat liver section (E) shows no expression
of  COX-2.
Fig. 3. Effect of Nexrutine on DEN/2-AAF-induced iNOS expression in rat liver. Livers of DEN/2-AAF-treated rats (B) showed overexpression of iNOS
compared to control livers (A). Treatment groups which were administered NX (300 ppm and 600 ppm) along with DEN/2-AAF (C and D, respectively)
showed reduction in iNOS overexpression compared to DEN/2-AAF alone.
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Fig. 4. Effect of Nexrutine on DEN/2-AAF-induced PCNA expression in rat liver. Livers of DEN/2-AAF-treated rats (B) showed overexpression of PCNA
compared to control livers (A). Rats treated with DEN/2-AAF along with 300 ppm NX (C) showed marginal reduction in PCNA overexpression, while addition
of  600 ppm NX (D) showed signiﬁcant reduction in PCNA overexpression in the liver compared to DEN/2-AAF treatment alone. NX (600 ppm)-treatment
alone  induced no expression of PCNA in the liver (E).is shown in Fig. 6A. Treatment with NX (0.5–20.0 g/ml) for
24 h decreased the cell viability by 12–66%; while, at 48 h,
the decrease in cell viability was even more pronounced
(16–88%). Based on these ﬁndings, we selected NX doses
of 2.5, 5.0 and 10.0 g/ml and 48 h time point for further
studies.
3.7. Nexrutine treatment induced apoptosis and cell
cycle arrest in liver cancer cells
In view of above mentioned growth inhibitory effect, we
were interested in determining whether NX also induces
apoptosis in liver cancer cells. It was observed that treat-
ment of liver cancer cells for 48 h with 2.5–10.0 g/ml NX
increases the number of apoptotic cells from 3.7 to 16.0%.
The total percent of apoptotic cells was directly related to
NX concentration increasing from 3.7% (control) to 16.0%
(10 g/ml), indicating that NX-induced apoptosis of liver
cancer cell is dose-dependent (Fig. 6C). As the induction
of apoptosis might also be mediated through the regula-
tion of the cell cycle, we also examined the effect of NX
treatment on cell cycle perturbations compared with the
vehicle alone treatment. As shown in Fig. 6B, exposure of
NX (2.5–10.0 g/ml) to liver cancer cells for 48 h resulted
in signiﬁcant increase in the proportion of cells in theG0/G1 phase (57–73%) with a concomitant decrease in the
S (10–19%) and G2/M (17–24%) phases.
3.8. Nexrutine treatment results in activation of intrinsic
pathway of apoptosis in liver cancer cells
Bax and Bcl-2 proteins play a central regulatory role
in apoptotic cell death. Therefore, the expression levels of
Bax and Bcl-2 following NX treatment were measured by
western blot analyses. As shown in Fig. 7A, NX treatment
(2.5–10.0 g/ml) resulted a dose-dependent increase in the
expression level of Bax and decrease in the expression level
of Bcl-2. To further conﬁrm whether modulation of Bax/Bcl-
2 ratio is correlated with the release of cytochrome c in
cytosol, the levels of cytochrome c in the cytosolic frac-
tion were measured. We  found the levels of cytochrome
c were signiﬁcantly elevated in a dose-dependent man-
ner following NX treatment as shown in Fig. 7A. It is well
documented that the apoptotic process is executed by
cysteinyl aspartate-speciﬁc proteases known as caspases,
which demolish the cell in an orderly fashion by cleaving a
large number of cellular protein substrates [21]. Therefore,
activation of caspases 3 and 9 was assessed after NX treat-
ment by western blot analyses. Results indicated that NX
treatment resulted in increased levels of cleaved-caspases
S. Alam et al. / Toxicology Reports 2 (2015) 1–11 7




























cas  investigated using TUNEL staining. An increase in the number of TUN
nd  D) compared to DEN/2-AAF-treated rats (B). However, the apoptotic
00  ppm of NX along with DEN/2-AAF (D).
 and 9 in a dose-dependent manner, while there was no
hange in expression level of caspase 8 (Fig. 7A).
.9. Nexrutine modulate cell cycle regulators and
hosphorylation of MAPKs
Altered expression of cell cycle regulatory protein such
s CDKs and cyclins has been implicated in tumorigene-
is [22,23]. As our results demonstrated inhibition of cell
roliferation upon NX treatment, we further examined it’s
ffect on the expression of cell regulatory proteins. As
hown in Fig. 7B, NX exposure caused a decrease in cyclinE,
yclinD1, CDK2 and CKD4 levels in liver cancer cells. During
ell cycle analysis we found that NX treatment caused G1
hase cell cycle arrest. We  also found from immunoblot
nalysis that NX treatment caused signiﬁcant induction
f p21WAF, a key regulator of G1-S phase transition, in
 dose-dependent manner (Fig. 7B). Kip1/p27 is another
mportant CDK inhibitor that regulates Cdk-cyclin activ-
ty at G1-S transition [24]. Protein levels of Kip1/p27 were
lso strongly upregulated after NX exposure. In addition,
e found that NX treatment to liver cancer cells caused
 dose-dependent increase expression of p53 (Fig. 7B).
urther, we investigated the level of activated (phosphory-
ated) and total ERK1/2, JNK and p38 kinases in NX-treated
epG2 cells and found phosphorylation of ERK1/2, JNK, and
38 kinase levels were downregulated by NX without any
hange in their total protein levels (Fig. 7C)tive cells was seen in the group that was treated with NX + DEN/2-AAF (C
on by NX was more pronounced in group where the rats are dosed with
4. Discussion
The present study we have shown that NX inhibited
2-AAF-mediated liver tumor promotion in DEN-initiated
rats, which was  correlated with a decrease in proliferation
index together with inhibition of COX-2, iNOS and PCNA
expression. Besides its anti-tumor promoting activity, we
also observed that NX causes apoptotic cell death to human
liver cancer cells.
Cancer development is a sequential event which often
involves chronic inﬂammation and hyperplasia. COX-2 is
well known biomarker of cell proliferation and tumor
promotion as it catalyzes the formation of prostaglandin
E2, which is reported to be involved in cell proliferation,
inﬂammation and angiogenesis [25]. Similarly, another
major mediator in chronic inﬂammatory processes is nitric
oxide (NO•), which is produced by liver parenchymal and
non-parenchymal cells from l-arginine via nitric oxide syn-
thase (NOS). NO• is considered to exert a hepatoprotective
action against tissue injury and cytotoxic effects due to
invading microorganisms, parasites and tumor cells. How-
ever, many situations that cause uncontrolled, prolonged
and/or massive production of NO• by inducible NOS (iNOS)
may  result in liver damage, leading to inﬂammation and
even tumor development [26]. iNOS produces much larger
amounts of NO• and has been detected in many human
tumors, such as breast cancer, melanoma, bladder cancer,
and colorectal cancer [27–30]. A considerable amount of
compelling evidence suggests that the inhibition of iNOS
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Fig. 6. Effect of Nexrutine on cell growth, cell cycle distribution and apoptosis. (A) Effect of NX on liver cancer cells (HepG2) growth. Liver cancer cells were
treated with NX (0.5–20.0 g/ml) for 24 and 48 h and the viability of cells was determined by the MTT  assay. The data are shown as the relative cell viability
compared to vehicle-treated control cells and represent the means ± S.E. of three experiments, in which each treatment was performed in multiple wells.
(*p  < 0.05 versus control). (B) Effect of NX on cell cycle phase distribution in liver cancer cells. The cells were treated with NX (2.5–10.0 g/ml) for 48 h and
harvested, stained with propidium iodide solution and data were acquired by ﬂow cytometry as described in text. The data are shown as percentage of
cells  in each phase and represent the mean ± S.E. of three experiments in which each treatment was performed in multiple ﬂasks. (C) Effect of Nexrutine on
induction of apoptosis in liver cancer cells as assessed by Annexin-V FITC staining. The cells were treated with NX (2.5–10.0 g/ml) for 48 h and collected,
stained with Annexin-V FITC (FITC-A; x-axis) and propidium iodide (PE-Texas Red; y-axis). The data were acquired by ﬂow cytometry as described in text
and  are shown as percentage of cells in Q2 quadrant (positive for both annexin V and PI) and tabulated as the mean ± S.E. of three experiments, in which
each  treatment was performed in multiple ﬂasks (*p < 0.05 versus control).
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Fig. 7. Effect of Nexrutine on proteins involved in apoptosis, cell cycle regulators and MAPK activation cascades in liver cancer (HepG2) cells. As detailed
in  text, the cells were treated with NX (2.5–10.0 g/ml) for 48 h and then harvested. Total cell lysates were prepared and 50 g protein was subjected to
sodium  dodecyl sulfate-polyacrylamide gel electrophoresis followed by western blot analyses. The membranes were probed for Bax, Bcl-2, caspases 3, 8,
9  and cytochrome c, cell cycle regulators and MAPKs, employing speciﬁc antibodies detailed in Section 2 followed by peroxidase-conjugated appropriate
















[he  blot and reprobing it for -actin or for total MAPK expression. The v
ompared to control after normalization with total protein or -actin.
nd COX-2 expression or activity is important not only for
reatment of chronic inﬂammation, but also for the preven-
ion of cancer [13,31,32]. Therefore, suppression of iNOS
nd COX-2 induction during cancer progression is recog-
ized as an important and commonly accepted approach
o effectively inhibit tumor promotion. These biomark-
rs were highly expressed in liver of DEN/2-AAF-treated
nimals. Treatment with NX remarkably suppressed COX-
 and iNOS in DEN/2-AAF-induced animals, suggesting a
lausible anti-tumor promotion role of NX in vivo. These
esults agree with earlier studies that have been shown
X to inhibit prostate, lung and skin cancer cell pro-
iferation by modulation of COX-2 and iNOS inhibition
8,12,13].ove the ﬁgures represent relative density in the term of fold change as
PCNA, is a 36 kDa nuclear protein and its expression in
the nucleus is associated with the DNA synthesis phase of
cell cycle, and serves as a biomarker of proliferation [20].
Earlier studies have reported that PCNA is highly associated
with DEN/2-AAF-induced liver carcinogenesis, which could
be detected immunohistochemically [33]. In our study, we
found that NX reduced the hepatic PCNA expression in
DEN/2-AAF treated rats.
Cell cycle regulation is one important mechanism of
anti-proliferation in cancers [34]. In the present study, we
investigated the cell cycle distribution after treatment with
NX and found accumulation of liver cancer cells at G1
phase of cell cycle. Similarly, earlier reports with skin and
prostate cancer cells showed NX treatment arrested cell
ology Re
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cycle progression at the G0/G1 phase [13]. Studies have also
suggested that regulation of cyclin activity plays a key role
in cell cycle progression at different phases, in which CDKs
are negatively regulated by a group of functionally related
proteins known as CDK inhibitors [24]. Cip/p21 binds and
inhibits the cyclins E1, D1 and Adependent kinases, regu-
lating the G1 to S phase transition of the cell cycle. Cip1/p21
is also known to inﬂuence the outcome of the p53 response
to DNA damage and plays a protective role in survival signal
against apoptosis. Kip1/p27 is up-regulated in response to
anti-proliferative signals [35,36]. In accordance with these
observations, our study also revealed an up-regulation of
Kip1/p27 and Cip1/p21, and a decrease in the levels of
CDK2, CDK4, cyclins E1 and D1 proteins. These results
provide a mechanism by which NX induces cell cycle arrest
that results in a decrease in cell proliferation of liver cancer
cells.
MAPKs are important upstream regulators of tran-
scription factor activation and their signaling is critical
to transduction of a wide variety of extracellular stimuli
into intracellular cascades, thereby controlling the cellular
events such as proliferation, differentiation and apoptosis
[37]. Our results demonstrated that NX treatment blocked
the phosphorylation, and hence, activation of MAPKs,
including ERK1/2 p38, and JNK in liver cancer cells. These
ﬁndings are similar to previous studies where inhibition
of ERK1/2, p38 and JNK by chemopreventive agents are
capable of preventing skin carcinogenesis [38,39].
Apoptotic cell death represents a universal and
exquisitely efﬁcient suicidal pathway and an ideal way  for
elimination of unwanted cells; however, cancerous cells
show dysregulation of this mechanism, which makes the
cells virtually immortal and resistant to stress stimuli as
well as therapeutic agents [40]. Therefore, the apoptotic
pathway is widely studied as a potential target for can-
cer chemotherapy [41,42]. In our study, NX treatment to
liver cancer cells resulted in a dose-dependent apoptotic
cell death, which would contribute to NX-mediated cell
growth inhibition. In support these ﬁndings, prior studies
have shown that various chemotherapeutic phytochemi-
cals possess the ability to induce apoptosis in cancer cells
by arresting the cell cycle progression in various phases of
cell division [43–45]. Furthermore, NX treatment to liver
cancer cells results in signiﬁcant decrease in the levels of
Bcl-2 protein along with an increase in the levels of Bax
protein, thus enhancing the Bax/Bcl-2 ratio, which favors
apoptosis. Increase in Bax/Bcl-2 ratio acts as a proapopto-
tic signal resulting in the release of cytochrome c protein
from mitochondria to cytoplasm, activating the apopto-
some, which further leads to auto-activation of caspase 9
and cleavage of pro-caspase 3 to its activated form cas-
pase 3, the executioner caspase [46–48]. Caspases are the
mediators of execution mechanism of apoptosis, and their
activation results in the cleavage of PARP protein, a DNA
repair enzyme in the cell, and subsequent DNA degradation
and apoptotic death [21]. Since, caspase 8 was not found
to be activated after NX treatment in liver cancer cells, it
can be deduced that NX-induced apoptosis is mediated via
activation of the intrinsic pathway.
In summary, this study demonstrated that NX inhibited
DEN/2-AAF-induced enhanced cell proliferation in liver. In
[ports 2 (2015) 1–11
addition, it also caused dose-as well as time-dependent
cytotoxicity in liver cancer (HepG2) cells. NX induced accu-
mulation of liver cancer cells at the G1 phase of cell cycle as
well as apoptosis. Taken together, these in vivo and in vitro
studies provide strong evidence that NX could be useful in
the management (chemoprevention as well as chemother-
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